Further investigation on the role of AKT3 in our cohort showed that estrogen- and progesterone-positive patients displayed longer cancer-specific survival where higher AKT3 levels (p = 0.006) were expressed supporting a possible predictive role for Tamoxifen response (see Supplementary file of results). This evidence concerns the gene AKT3 and cancer.